Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity
Authors:
Open Access
- 1 August 2020
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 880, 173196
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Thrombomodulin alfa attenuates thrombin-induced leakage of antithrombin through suppression of endothelial vascular hyperpermeabilityThrombosis Research, 2017
- Kinin Receptors Sensitize TRPV4 Channel and Induce Mechanical Hyperalgesia: Relevance to Paclitaxel-Induced Peripheral Neuropathy in MiceMolecular Neurobiology, 2017
- Potentiation of Paclitaxel-Induced Pain Syndrome in Mice by Angiotensin I Converting Enzyme Inhibition and Involvement of KininsMolecular Neurobiology, 2016
- Effect of synthetic eel calcitonin, elcatonin, on cold and mechanical allodynia induced by oxaliplatin and paclitaxel in ratsEuropean Journal of Pharmacology, 2012
- Thrombin activatable fibrinolysis inhibitor: At the nexus of fibrinolysis and inflammationThrombosis Research, 2012
- Thrombin-Cofactor InteractionsArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFRCancer Chemotherapy and Pharmacology, 2005
- The interactions between inflammation and coagulationBritish Journal of Haematology, 2005
- The Protein C PathwayChest, 2003
- A good practice guide to the administration of substances and removal of blood, including routes and volumesJournal of Applied Toxicology, 2001